Daily Endocrinology Research Analysis
Three impactful studies span social determinants, pharmacotherapy in secondary diabetes, and neurodevelopment in pediatric type 1 diabetes. A 1.84-million–person cohort links low income and income instability to higher severe hypoglycemia risk, a Korean nationwide study shows SGLT2 inhibitors reduce MACE, heart failure, ESKD, and mortality in diabetes secondary to exocrine pancreas disorders, and a longitudinal MRI study ties dysglycemia to persistent white matter microstructural differences in
Summary
Three impactful studies span social determinants, pharmacotherapy in secondary diabetes, and neurodevelopment in pediatric type 1 diabetes. A 1.84-million–person cohort links low income and income instability to higher severe hypoglycemia risk, a Korean nationwide study shows SGLT2 inhibitors reduce MACE, heart failure, ESKD, and mortality in diabetes secondary to exocrine pancreas disorders, and a longitudinal MRI study ties dysglycemia to persistent white matter microstructural differences in children with type 1 diabetes.
Research Themes
- Socioeconomic determinants and hypoglycemia risk in type 2 diabetes
- Cardio-renal protection with SGLT2 inhibitors in pancreatogenic diabetes
- Dysglycemia-linked white matter changes in pediatric type 1 diabetes
Selected Articles
1. Income and Severe Hypoglycemia in Type 2 Diabetes.
Using Korean NHID (n=1,838,362) and UK Biobank (n=17,287), lower income and medical aid status were strongly associated with higher risk of severe hypoglycemia, while upward income mobility over 5 years reduced risk. Associations were stronger in men, those not using insulin, those without CKD, and shorter diabetes duration.
Impact: Defines socioeconomic drivers of severe hypoglycemia at population scale and demonstrates risk modification with income changes, informing targeted clinical and policy interventions.
Clinical Implications: Screen for socioeconomic risk (e.g., low income/medical aid), integrate social support, simplify regimens, expand CGM access, and prioritize education to mitigate hypoglycemia. Health systems should consider subsidizing technologies and medications for low-income patients.
Key Findings
- Low income associated with higher severe hypoglycemia risk: NHID HR 2.50 (95% CI 2.33–2.57); UKBB HR 5.38 (95% CI 1.72–16.85).
- Upward income mobility from lowest/medical aid to highest quartile over 5 years reduced risk (HR 0.74; 95% CI 0.67–0.81).
- Medical aid status ≥1 year increased risk (HR 1.71; 95% CI 1.54–1.89).
- Stronger associations in men, non–insulin users, those without CKD, and shorter diabetes duration.
Methodological Strengths
- Very large national cohort with replication in an independent biobank.
- Assessment of income dynamics over 5 years and subgroup analyses.
Limitations
- Observational design with residual confounding and potential misclassification of income or events.
- Generalizability may differ across healthcare systems and social safety nets.
Future Directions: Test targeted interventions (CGM subsidy, education, simplified regimens) in low-income populations; integrate SDOH data into risk stratification models.
IMPORTANCE: Socioeconomic disparities are increasingly recognized as key factors in health outcomes among patients with type 2 diabetes. Understanding how income level and its changes are associated with severe hypoglycemia risk may inform targeted interventions and policy decisions. OBJECTIVE: To evaluate the association between income level, including changes in income status, and the risk of severe hypoglycemia, and to assess whether this association varies across key subgroups in middle-aged adults. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included adults aged 40 to 70 years with type 2 diabetes from the Korean National Health Information Database (NHID) who underwent health examinations from 2015 to 2016. Participants aged 40 to 70 years with type 2 diabetes and valid income information were recruited between 2006 and 2010 from the UK Biobank (UKBB) and were included for sensitivity analysis. Data were analyzed from January 2023 to September 2024. EXPOSURES: Participants were categorized into annual income quartiles (NHID) or self-reported income brackets (UKBB). In the NHID, medical aid beneficiaries (ie, those receiving government medical aid due to income below 40% of the median income and limited assets) were identified, and income changes over a 5-year period were assessed. MAIN OUTCOMES AND MEASURES: Severe hypoglycemia requiring medical intervention. RESULTS: Among 1 838 362 adults with type 2 diabetes from the NHID (mean [SD] age, 57.1 [8.1] years; 1 157 263 [63.0%] male) and 17 287 participants from the UKBB (mean [SD] age, 56.9 [6.8] years; 11 522 [66.7%] male), lower income was associated with a higher risk of severe hypoglycemia (NHID: hazard ratio [HR], 2.50; 95% CI, 2.33-2.57; UKBB: HR, 5.38; 95% CI, 1.72-16.85). In the NHID, individuals whose income increased from the lowest quartile or medical aid status to the fourth quartile over 5 years had a significantly lower risk (HR, 0.74; 95% CI, 0.67-0.81; P for trend <.001), whereas receiving medical aid for at least 1 year was associated with a significantly higher risk (HR, 1.71; 95% CI, 1.54-1.89). The association between income and severe hypoglycemia was consistently greater in men, individuals not using insulin, those without chronic kidney disease, and those with a shorter duration of diabetes. CONCLUSIONS AND RELEVANCE: In this cohort study of adults with type 2 diabetes, low income was found to be a significant factor associated with risk for severe hypoglycemia. Addressing socioeconomic disparities and implementing targeted interventions may help reduce the incidence and severity of hypoglycemia.
2. Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study.
In a matched nationwide cohort of 4,128 pairs with pancreatogenic diabetes, SGLT2 inhibitors lowered risks of MACE, heart failure hospitalization, ESKD, and all-cause mortality compared with other glucose-lowering drugs. Safety signals were favorable, with reduced urinary tract infections and pancreatitis.
Impact: Provides first large-scale real-world evidence that SGLT2 inhibitors confer broad cardio-renal and survival benefits in diabetes secondary to exocrine pancreas disorders, a neglected population with high risk.
Clinical Implications: Consider SGLT2 inhibitors as foundational therapy in pancreatogenic diabetes for cardio-renal risk reduction, with monitoring similar to type 2 diabetes. Tailor therapy to exocrine insufficiency context and nutritional status.
Key Findings
- SGLT2 inhibitors reduced MACE risk vs. other GLDs (HR 0.69; 95% CI 0.51–0.93).
- Lower hospitalization for heart failure (HR 0.70; 95% CI 0.51–0.95).
- Marked reduction in ESKD (HR 0.19; 95% CI 0.06–0.61).
- Lower all-cause mortality (HR 0.38; 95% CI 0.27–0.53).
- Safety: reduced urinary tract infections (HR 0.87) and pancreatitis (HR 0.71).
Methodological Strengths
- Nationwide database with large sample and propensity-score matching.
- Comprehensive outcomes including MACE, HF, ESKD, mortality, and safety events.
Limitations
- Observational design with potential residual confounding and channeling bias.
- Claims-based outcome definitions may introduce misclassification; limited granularity on disease phenotype and dosing.
Future Directions: Prospective trials in pancreatogenic diabetes to confirm benefits and define subgroups; evaluate combination strategies and effects on exocrine pancreatic outcomes.
AIMS: Limited data are available on the effectiveness of pharmacological treatments for diabetes secondary to disorders of the exocrine pancreas (DEP). This study evaluated the real-world effectiveness and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with DEP. METHODS: A retrospective cohort study was conducted using data from the Korean National Health Insurance Service database. Data on 66,120 individuals with DEP who initiated glucose-lowering drugs (GLDs) between September 2014 and December 2022 were analyzed. Patients initiating SGLT2 inhibitors were matched 1:1 with patients initiating other GLDs using propensity-score matching. The effectiveness outcomes included major adverse cardiovascular events (MACEs), heart failure, end-stage kidney disease (ESKD), and all-cause mortality. The safety outcomes included hypoglycemia, diabetic ketoacidosis, genital infections, urinary tract infections, fractures, pancreatitis, and pancreatic cancer. RESULTS: After matching, 4,128 SGLT2 inhibitor-other GLD user pairs were included in the analysis, with a mean follow-up of 2.3 years. Compared with use of other GLDs, use of SGLT2 inhibitors was associated with a significantly lower risk of MACE (hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.51-0.93), hospitalization for heart failure (HR: 0.70; 95% CI: 0.51-0.95), ESKD (HR: 0.19; 95% CI: 0.06-0.61), and all-cause mortality (HR: 0.38; 95% CI: 0.27-0.53). SGLT2 inhibitor use was associated with a reduced risk of urinary tract infections (HR: 0.87; 95% CI: 0.78-0.96) and pancreatitis (HR 0.71; 95% CI 0.58-0.87). CONCLUSIONS: SGLT2 inhibitors were associated with a reduced risk of adverse cardiorenal outcomes and all-cause mortality and were safely used in patients with DEP.
3. Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow-up: Relation to Dysglycemia.
Over 6–8 years and four MRI assessments, both T1D and controls showed maturation trends (↑FA; ↓RD/AD/MD), but children with T1D had lower axial diffusivity at ages 6–10, with differences attenuating by puberty. Higher glucose and lower time-in-range were linked to lower FA and higher RD/MD; higher time-in-range correlated with better FA and cognitive metrics.
Impact: Provides longitudinal, multimodal evidence linking dysglycemia to developing brain white matter microstructure and cognition, highlighting the importance of tight glycemic control in childhood.
Clinical Implications: Supports early and sustained glycemic optimization (e.g., higher time-in-range via CGM-enabled care) to protect neurodevelopment. Encourages integrating neurocognitive monitoring in pediatric T1D management.
Key Findings
- Across 6–8 years and four time points, FA increased and RD/AD/MD decreased in both groups, reflecting maturation.
- Children with T1D had lower axial diffusivity than controls at ages 6–10; differences were not detected at age ~12 (puberty).
- Higher glucose levels associated with lower FA and higher RD/MD; higher time-in-range associated with higher FA and better cognitive metrics.
- Within T1D, AD and MD were not linked to neurocognitive outcomes.
Methodological Strengths
- Prospective longitudinal design with 4 MRI time points over 6–8 years.
- Mixed-effects modeling integrating DTI metrics, CGM-derived glycemia, and cognition.
Limitations
- Attrition across time points and imputed age at puberty may affect precision.
- Potential scanner/protocol variability and generalizability beyond study centers.
Future Directions: Interventional studies to determine whether improving time-in-range modifies white matter trajectories and cognition; mechanistic work linking glucose variability to myelination.
UNLABELLED: Type 1 diabetes has detrimental effects in white matter microstructure. In a longitudinal study, we investigated whether these reported findings change as children grow and enter puberty. At study entry, there were 143 children with type 1 diabetes and 71 control participants without diabetes, 4-9 years old. Brain MRI using diffusion tensor imaging, neurocognitive, and glycemic assessments were performed four times across 6-8 years of follow-up. Longitudinal mixed-effects modeling was used to examine changes in fractional anisotropy (FA), axial diffusivity (AD) (measures of myelination and fiber integrity), radial diffusivity (RD) (axonal leakage), and mean diffusivity (MD) (average diffusion). Associations with glycemic and cognitive measures were assessed. We observed in 182 children (121 type 1 diabetes vs. 61 control participants) who had testing at time 4 that FA increased, and RD, AD, and MD decreased significantly in both groups, with no differences between groups for FA, RD and MD over time. However, children with diabetes had lower AD than control participants at 6-10 years. Differences were not detected at 12 years (age imputed from data), when in puberty. Higher blood glucose levels are associated with lower FA and higher RD and MD. Higher glucose percentage time-in-range was associated with higher FA, reflecting better fiber integrity and myelination and higher cognitive metrics. Within the diabetes group, AD and MD showed no association with neurocognitive outcomes. In summary, white matter AD was decreased in children with diabetes, less so during puberty, and FA was reciprocally related to hyperglycemia. These data suggest continued negative impact of chronic hyperglycemia in the developing brain. ARTICLE HIGHLIGHTS: Type 1 diabetes has detrimental effects in white matter in young children. We performed a longitudinal study using brain MRI (diffusion tensor imaging) and cognitive assessments in 4- to 9-year-old children, control participants without diabetes (n = 71) and with type 1 diabetes (n = 143), plus continuous glucose monitoring, to assess changes at four time points as children grow over 6-8 years. White matter myelination and fiber integrity were assessed using axial diffusivity, which was decreased in the diabetes versus control group, less so during puberty, and fractional anisotropy was reciprocally related to hyperglycemia. Data suggest continued negative impact of chronic hyperglycemia in the developing brain.